| Theme |
GIST : Current Progress on Diagnosis and Treatment |
| Title |
Risk Classification for Gastrointestinal Stromal Tumors (GISTs) |
| Author |
Takahiko Nakajima |
Department of Diagnostic Pathology, NTT Medical Center Tokyo |
| Author |
Atsushi Kihara |
Department of Diagnostic Pathology, NTT Medical Center Tokyo |
| Author |
Shougo Tajima |
Department of Diagnostic Pathology, NTT Medical Center Tokyo |
| Author |
Kenichirou Murata |
Department of Diagnostic Pathology, NTT Medical Center Tokyo |
| Author |
Shouji Matsuya |
Department of Diagnostic Pathology, NTT Medical Center Tokyo |
| Author |
Hajime Horiuchi |
Department of Diagnostic Pathology, NTT Medical Center Tokyo |
| Author |
Toshiro Sugiyama |
Department of Gastroenterology and Hematology, Faculty of Medicine, University of Toyama |
| [ Summary ] |
There are no criteria for distinguishing benign gastrointestinal stromal tumors (GISTs) from malignant ones. Althogh most small GISTs follow a favorable clinical course, patients occasionally develop metastases. The National Institutes of Health (NIH)consensus scheme, which is based on tumor size and mitotic activity, has been widely accepted to assess the potential risk of GISTs, To better assess the malignant potential of GISTs. in relation to targeting adjuvant therapy, new risk classifications have been proposed. The enhanced classification system which additionally takes into consideration the tumor site, highlights the higher malignancy potential of tumors in the small intestine versus gastric GISTs. |